47 related articles for article (PubMed ID: 20415625)
1. Intravitreal triamcinolone acetonide for exudative age related macular degeneration.
Jonas JB; Kreissig I; Hugger P; Sauder G; Panda-Jonas S; Degenring R
Br J Ophthalmol; 2003 Apr; 87(4):462-8. PubMed ID: 12642311
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05.
Koch R; Schmidt M; Gebauer S; Busse H; Uhlig CE
BMC Ophthalmol; 2015 Oct; 15():138. PubMed ID: 26490832
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration.
Riazi-Esfahani M; Ahmadieh H; Faghihi H; Piri N; Taei R; Karkhaneh R; Alami-Harandi Z; Lashay A; Mirshahi A; Nili-Ahmadabadi M; Soheilian M; Sanagou M
J Ophthalmic Vis Res; 2008 Apr; 3(2):95-101. PubMed ID: 23479530
[TBL] [Abstract][Full Text] [Related]
4. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial).
Menon G; Chandran M; Sivaprasad S; Chavan R; Narendran N; Yang Y
Eye (Lond); 2013 Aug; 27(8):959-63. PubMed ID: 23743535
[TBL] [Abstract][Full Text] [Related]
5. Treatment of exudative age-related macular degeneration: many factors to consider.
Olsen TW
Am J Ophthalmol; 2007 Aug; 144(2):281-3. PubMed ID: 17659955
[No Abstract] [Full Text] [Related]
6. Bevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting.
Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
Int J Ophthalmol; 2016; 9(3):424-30. PubMed ID: 27158614
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal panitumumab and myopic macular degeneration.
Bikbov MM; Kazakbaeva GM; Holz FG; Panda-Jonas S; Gilemzianova LI; Khakimov DA; Jonas JB
Br J Ophthalmol; 2024 May; 108(6):859-864. PubMed ID: 37429701
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab: an analysis of the evidence.
Smit DP; Meyer D
Clin Ophthalmol; 2007 Sep; 1(3):273-84. PubMed ID: 19668481
[TBL] [Abstract][Full Text] [Related]
9. Statins and the progression of age-related macular degeneration in the United States.
Ludwig CA; Vail D; Rajeshuni NA; Al-Moujahed A; Rosenblatt T; Callaway NF; Veerappan Pasricha M; Ji MH; Moshfeghi DM
PLoS One; 2021; 16(8):e0252878. PubMed ID: 34347799
[TBL] [Abstract][Full Text] [Related]
10. Computer Modeling of Bevacizumab Drug Distribution After Intravitreal Injection in Rabbit and Human Eyes.
Chowdhury JM; Ruiz EAC; Swindle-Reilly KE; Versypt ANF
bioRxiv; 2024 Jan; ():. PubMed ID: 37215026
[TBL] [Abstract][Full Text] [Related]
11. Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration.
Navarro-Partida J; Altamirano-Vallejo JC; Aceves Franco LA; Gonzalez-Cortes J; Hernandez-Da Mota S; García-Aguirre JG; Azuara-Galindo CD; Castro-Castaneda CR; Armendariz-Borunda J; Santos A
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575567
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options.
Wallsh JO; Gallemore RP
Cells; 2021 Apr; 10(5):. PubMed ID: 33946803
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Bevacizumab with or without Triamcinolone for Wet Age-related Macular Degeneration: Twelve-month Results of a Prospective, Randomized Investigation.
Motarjemizadeh Q; Aidenloo NS; Abbaszadeh M; Sadrinia V
Middle East Afr J Ophthalmol; 2018; 25(1):1-7. PubMed ID: 29899643
[TBL] [Abstract][Full Text] [Related]
14. Oral Doxycycline Reduces the Total Number of Intraocular Bevacizumab Injections Needed to Control Neovascular Age-related Macular Degeneration.
Mirshahi A; Azimi P; Abdolahi A; Mirshahi R; Abdollahian M
Med Hypothesis Discov Innov Ophthalmol; 2017; 6(2):23-29. PubMed ID: 29367931
[TBL] [Abstract][Full Text] [Related]
15. Epithelial membrane protein 2 controls VEGF expression in ARPE-19 cells.
Morales SA; Telander DG; Leon D; Forward K; Braun J; Wadehra M; Gordon LK
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2367-72. PubMed ID: 23439602
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapeutic approaches in the management of retinal angiogenesis and edema.
Truong A; Wong TY; Khachigian LM
J Mol Med (Berl); 2011 Apr; 89(4):343-61. PubMed ID: 21170513
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
Tao Y; Jonas JB
J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
Forte R; Cennamo G; Finelli M; Cesarano I; D'Amico G; De Crecchio G; Cennamo G
Acta Ophthalmol; 2010 Dec; 88(8):e305-10. PubMed ID: 20946332
[TBL] [Abstract][Full Text] [Related]
19. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
